Galectin Therapeutics (GALT) News Today $1.28 -0.04 (-3.03%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)April 2 at 11:59 PM | markets.businessinsider.comGalectin Therapeutics reports FY24 EPS (76c) vs (74c) last yearApril 2 at 9:26 AM | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPSGalectin Therapeutics (NASDAQ:GALT - Get Free Report) issued its earnings results on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03).April 1 at 9:55 AM | marketbeat.comGalectin Therapeutics Reports 2024 Financial Results and Provides Business UpdateMarch 31 at 8:00 AM | globenewswire.comGalectin Therapeutics (GALT) to Release Quarterly Earnings on FridayGalectin Therapeutics (NASDAQ:GALT) will be releasing earnings before the market opens on Friday, April 4, Financial Modeling Prep reports.March 28, 2025 | marketbeat.comWhile insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownershipMarch 8, 2025 | finance.yahoo.comGalectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE TrialFebruary 18, 2025 | markets.businessinsider.comGalectin Therapeutics’ belapectin shows reduction in new varicesFebruary 18, 2025 | markets.businessinsider.comGalectin Therapeutics shareholders elect directors, ratify auditorJanuary 29, 2025 | msn.comInvestors Purchase High Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 15,740 put options on the stock. This is an increase of 230% compared to the typical volume of 4,772 put options.January 15, 2025 | marketbeat.comGalectin Therapeutics to Present at the 2025 MASH-TAG ConferenceJanuary 10, 2025 | globenewswire.comGalectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell"StockNews.com lowered Galectin Therapeutics from a "hold" rating to a "sell" rating in a report on Monday.December 30, 2024 | marketbeat.comShort Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Increases By 41.1%Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 8,270,000 shares, a growth of 41.1% from the November 30th total of 5,860,000 shares. Currently, 19.0% of the company's shares are sold short. Based on an average daily volume of 494,900 shares, the short-interest ratio is currently 16.7 days.December 30, 2024 | marketbeat.comHC Wainwright & Co. Downgrades Galectin Therapeutics (GALT)December 28, 2024 | msn.comGalectin Therapeutics downgraded to Neutral from Buy at H.C. WainwrightDecember 27, 2024 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Earns Neutral Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Galectin Therapeutics in a research note on Friday.December 27, 2024 | marketbeat.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of StockDecember 27, 2024 | insidertrades.comKhurram Jamil Sells 13,654 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) insider Khurram Jamil sold 13,654 shares of Galectin Therapeutics stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.88, for a total transaction of $12,015.52. Following the completion of the transaction, the insider now directly owns 26,346 shares of the company's stock, valued at approximately $23,184.48. This represents a 34.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 26, 2024 | marketbeat.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells 40,000 Shares of StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CFO Jack W. Callicutt sold 40,000 shares of the business's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $35,600.00. Following the completion of the transaction, the chief financial officer now directly owns 7,614 shares of the company's stock, valued at $6,776.46. The trade was a 84.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.December 26, 2024 | marketbeat.comGalectin Therapeutics Inc. (NASDAQ:GALT) CEO Sells 56,000 Shares of StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 56,000 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the sale, the chief executive officer now owns 897,012 shares of the company's stock, valued at $798,340.68. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.December 26, 2024 | marketbeat.comWhy Is Galectin Stock Falling In Pre-market?December 20, 2024 | markets.businessinsider.comGalectin drops as trial for lead asset fails in MASHDecember 20, 2024 | seekingalpha.comGalectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASHDecember 20, 2024 | globenewswire.comStock Traders Purchase Large Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 14,331 put options on the stock. This represents an increase of 557% compared to the average daily volume of 2,182 put options.December 16, 2024 | marketbeat.comAlibaba Stock Rips Higher As China Vows Serious Stimulus, But Is BABA Stock A Buy Now?December 10, 2024 | yahoo.comGalectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday.November 20, 2024 | marketbeat.comGalectin Therapeutics presents three abstracts at AASLD 2024 Liver MeetingNovember 18, 2024 | markets.businessinsider.comGalectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingNovember 18, 2024 | globenewswire.comHC Wainwright Has Bearish Estimate for GALT FY2027 EarningsGalectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright dropped their FY2027 earnings estimates for shares of Galectin Therapeutics in a research note issued on Friday, November 15th. HC Wainwright analyst E. Arce now expects that the company will post earnings ofNovember 18, 2024 | marketbeat.comOptimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost ProspectsNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics Reports Increased Q3 LossesNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics (NASDAQ:GALT) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business UpdateNovember 14, 2024 | globenewswire.comInsider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases 5,000 Shares of StockOctober 17, 2024 | insidertrades.comGalectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) Director Kevin D. Freeman bought 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average price of $2.70 per share, with a total value of $13,500.00. Following the completion of the transaction, the director now directly owns 33,469 shares of the company's stock, valued at $90,366.30. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.October 16, 2024 | marketbeat.comGalectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingOctober 15, 2024 | globenewswire.comGalectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.comStockNews.com upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday.October 15, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.comStockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday.October 6, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.comStockNews.com downgraded Galectin Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.September 28, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.comStockNews.com raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.September 20, 2024 | marketbeat.comCommonwealth Equity Services LLC Buys 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT)Commonwealth Equity Services LLC increased its stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 317.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 483,351 shares of the company's stock after buying an adSeptember 17, 2024 | marketbeat.comGalectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comGalectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Growth in Short InterestGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 5,010,000 shares, a growth of 6.4% from the July 31st total of 4,710,000 shares. Currently, 11.6% of the shares of the company are sold short. Based on an average daily trading volume, of 165,400 shares, the days-to-cover ratio is currently 30.3 days.September 2, 2024 | marketbeat.comStock Traders Purchase Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 2,501 put options on the company. This is an increase of approximately 1,282% compared to the average daily volume of 181 put options.August 29, 2024 | marketbeat.comBuy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and with Strong Cash PositionAugust 21, 2024 | markets.businessinsider.comHC Wainwright Comments on Galectin Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a note issued to investors on Friday, August 16th. HC Wainwright analyst E. Arce forecasts that the company willAugust 19, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Galectin Therapeutics (NASDAQ:GALT)HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Galectin Therapeutics in a report on Friday.August 16, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Announces Earnings ResultsGalectin Therapeutics (NASDAQ:GALT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04).August 15, 2024 | marketbeat.comGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business UpdateAugust 13, 2024 | globenewswire.comGalectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical OfficerAugust 1, 2024 | globenewswire.com Remove Ads Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address GALT Media Mentions By Week GALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GALT News Sentiment▼-0.190.57▲Average Medical News Sentiment GALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GALT Articles This Week▼71▲GALT Articles Average Week Remove Ads Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTC News CYRX News ATXS News AURA News ALMS News ARCT News AQST News SLDB News GLUE News TSHA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GALT) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GALT Stock Free GALT Stock Alerts